Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00477269 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

A Phase 2 study, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
59
Enrollment target

NCT00477269: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.

NCT00477269 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00477269, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
59 participants
Enrollment target

Study Summary

This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension

Primary Outcome

In this analysis patients with all (serious and non -serious) adverse events, and death were reported. See Safety Section.

Interventions

  • DRUG Placebo
  • DRUG Imatinib mesylate

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2006-04
Est. Completion 2014-01
Phase Phase 2
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT00477269 record still lists

NCT00477269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00477269 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00477269 about?

NCT00477269 is a clinical study titled "Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension". This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension

What is the current status of trial NCT00477269?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2006-04. Estimated completion is 2014-01.

What interventions are being tested in trial NCT00477269?

The interventions under investigation include: Placebo (DRUG), Imatinib mesylate (DRUG).

Who is sponsoring clinical trial NCT00477269?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00477269's enrollment target sits among peer trials

59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03801083 · 59 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

  • NCT04332367 · 59 participants · Phase 2

    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  • NCT05489575 · 59 participants · NA

    CPAP for the Treatment of Supine Hypertension

  • NCT06721689 · 59 participants · Phase 1

    PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00477269, the US trial registry maintained by the National Library of Medicine. NCT00477269 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.